Andrea S. Blevins Primeau, PhD, MBA

A single-arm cohort study sought to determine the efficacy of adding samuraciclib to treatment for ER-positive and/or PGR-positive, HER2-negative breast cancer.

An analysis of patients in the INSEMA trial sought to determine the impact of no SLNB vs SLNB and SLNB alone vs SLNB with ALND on quality of life for patients with breast cancer.

Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.

An analysis evaluated outcomes for patients with breast cancer who were treated with a modern approach compared with a historical standard approach.

Palbociclib added to adjuvant endocrine therapy failed to improve iDFS.

The delay in clip placement was associated with significant anxiety among the patients who were interviewed.

Adjuvant pembrolizumab prolongs relapse-free survival, when compared with placebo, in patients with resected, stage II melanoma.

The addition of nivolumab to chemotherapy demonstrated continuing improved survival compared with chemotherapy alone after 24 months of follow-up.

The median PFS was 8.0 months with TARE and 7.2 months with chemotherapy alone.

Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.